石家庄以岭药业股份有限公司 关于实际控制人部分股份质押展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 石家庄以岭药业股份有限公司（以下简称"公司"或"本公司"）于2025年12月19日接到公司实际控制人吴 瑞的通知，获悉吴瑞所持有本公司的部分股份办理质押展期，具体事项如下： 一、股东部分股份质押展期的基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002603 证券简称：以岭药业 公告编号：2025-052 （注：吴相君、吴瑞所持限售股份性质为高管锁定股，故上表中的"已质押股份限售和冻结数量"及"未 质押股份限售和冻结数量"均系高管锁定股。） 吴瑞女士资信状况良好，具备良好的资金偿还能力，质押风险可控，不存在实质性资金偿还风险。上述 质押展期行为不会导致公司实际控制权发生变更、不会对公司生产经营和公司治理产生影响。若出现平 仓风险，吴瑞女士将采取补充质押、提前购回被质押股份等措施应对风险。 二、备查文件 1、广发证券股份有限公司股票质押交易确认书； 2、中国证券登记结算有限责任公司股份冻结明细。 特此公告。 石家庄以岭药业股份 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002603 证券简称：以岭药业 公告编号：2025-052 石家庄以岭药业股份有限公司 关于实际控制人部分股份质押展期的公告 石家庄以岭药业股份有限公司（以下简称"公司"或"本公司"）于2025年12月 19日接到公司实际控制人吴瑞的通知，获悉吴瑞所持有本公司的部分股份办理质 押展期，具体事项如下： 一、股东部分股份质押展期的基本情况 | 股东名 | 是否为控股 股东或第一 | 本次质押展 | 占其所 | 占公司 | 是否为 | 是否为补 | 原质押起 | | 展期后到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 大股东及其 | 期数量（股） | 持股份 | 总股本 | 限售股 | 充质押 | 始日 | | 期日 | 质权人 | 用途 | | | 一致行动人 | | 比例 | 比例 | | | | | | | | | 吴瑞 | 公司实际控 | 2,600,000 | 6 ...

12月16日，由上海报业集团指导、智通财经主办的2025第八届界面财经年会在上海举行。在颁奖典礼中 发布了系列荣誉榜单，以岭药业荣获2025【常春奖】年度中医药创新杰出企业。 据悉，本次评选聚焦大健康行业的升级和变化，围绕业务标准、市场占比、模式创新、品牌美誉等维 度，综合社会各界的意见与建议，涵盖制药、医疗器械、互联网医疗、医疗机构、消费保健等领域，旨 在通过榜单致敬那些心怀悲悯之心，秉持向上之力，为改变人类身心痛苦而埋头进取的公司与个人。 企业的核心竞争力源于对研发创新的长期坚守。数据显示，2025年前三季度，以岭药业研发费用达5.44 亿元，占营业收入比重9.27%。近年来，公司研发投入持续处于行业领先水平，2019至2024年间累计研 发投入已超过50亿元。高强度的研发投入直接转化为丰硕的创新成果。2025年，以岭药业中药1.1类新 药芪防鼻通片获国家药监局批准上市，后成功在澳门注册上市，成为澳门首个注册上市的中成药创新 药，日前被纳入国家新版医保目录。目前，公司已研发上市17个专利中药，覆盖心脑血管、呼吸系统、 内分泌系统等重大疾病领域。此外，包括芪桂络痹通片、小儿连花清感颗粒在内的多款中药新药已进 ...

证券研究报告 2025 年 12 月 14 日 湘财证券研究所 行业研究 中药行业周报 全国医保工作会议召开，价格与市场格局重塑仍是 2026 中药行业大方向 相关研究： 核心要点： ❑ 市场表现：上周中药Ⅱ下跌 2.03%，跌幅相对较大 根据 wind 数据，上周（2025.12.07-2025.12.13）医药生物报收 8280.55 点，下跌 1.04%；中药Ⅱ报收 6372.09 点，下跌 2.03%；化学制药报收 13271.69 点，下跌 0.75%；生物制品报收 6234.22 点，下跌 1.85%；医药商业报收 5257.6 点，下跌 4.26%；医疗器械报收 6373.39 点，下跌 1.79%；医疗服务报收 6344.37 点，上涨 1.67%。医药二级子板块中，仅医疗服务录得正收益，其他板块均回调，中药 板块跌幅相对较大。 从公司表现来看，根据 wind 数据，表现居前的公司有：佐力药业、江中药业、 葵花药业、东阿阿胶、马应龙；表现靠后的公司有：粤万年青、太龙药业、信 邦制药、益盛药业、维康药业。 ❑ 估值：上周中药板块 PE（ttm）为 27.17X，PB（lf）为 2.29X 根据 ...

Core Viewpoint - The rising demand for travel protection due to respiratory diseases has led to a collaboration between Yiling Health and Shenzhou Car Rental, launching the "New Year Journey" campaign to provide health products for users during year-end travel [1] Group 1: Product Offerings - The campaign features the Lianhua Respiratory Health product series, which utilizes the patented Lianhua HAbO essential oil to create a comprehensive protective system [1] - The Lianhua mask bead, praised as an "air renewal artifact" for in-car protection, releases essential oil upon squeezing, alleviating discomfort from prolonged mask use [2] - Additional products include the Lianhua throat spray for soothing, Lianhua sugar-free herbal candy for throat relief, and Lianhua plant beverage for hydration, all aimed at enhancing travel comfort [2] Group 2: Market Positioning - Yiling Health aims to meet diverse travel needs across various demographics, including commuters and students, by providing a health barrier through its product offerings [4] - The company plans to continue focusing on consumer protection needs in different life scenarios, integrating traditional Chinese medicine with modern technology for respiratory health [4] - The comprehensive protective logic of the Lianhua Respiratory Health series is designed to ensure safe and healthy travel experiences for users [4]

Core Viewpoint - The company emphasizes the importance of continuous innovation in drug development to adapt to the evolving pharmaceutical industry and ensure effective clinical outcomes [2] Company Insights - The company, Shijiazhuang Yiling Pharmaceutical Co., Ltd., stresses the need for increased investment in innovative drugs to maintain competitiveness in the market [2] - The company believes that having comprehensive and robust evidence to support the efficacy of its products is crucial for success across different market cycles [2]

Core Insights - A total of 553 stocks in the Shanghai and Shenzhen markets have experienced net outflows of main funds for five consecutive days or more as of December 10 [1] - ST Jinglan has the longest streak of net outflows, with 23 days, followed by Aier Eye Hospital with 22 days [1] - The largest total net outflow amount is from Changcheng Military Industry, which has seen a cumulative outflow of 2.123 billion yuan over 12 days [1] Summary by Category Stocks with Longest Net Outflow Duration - ST Jinglan: 23 days of net outflow [1] - Aier Eye Hospital: 22 days of net outflow [1] - Sairisi: 7 days of net outflow [1] Stocks with Largest Net Outflow Amount - Changcheng Military Industry: 2.123 billion yuan over 12 days [1] - Aier Eye Hospital: 1.706 billion yuan over 22 days [1] - Sairisi: 1.370 billion yuan over 7 days [1] Stocks with Highest Net Outflow Proportion - *ST Zhengping: 26.44% decline over the last 5 days [1] - Aier Eye Hospital: 14.30% decline over 22 days [1] - Sairisi: 11.26% decline over 7 days [1] Additional Notable Stocks - Keda Xunfei: 1.209 billion yuan net outflow over 12 days with a 2.75% decline [1] - Dongfang Precision: 1.171 billion yuan net outflow over 7 days with a 10.92% decline [1] - Huaying Technology: 939 million yuan net outflow over 5 days with a 7.32% decline [1]

12月8日，阿里健康和以岭药业（002603）签署战略合作协议。双方宣布以岭药业一类创新中药芪防鼻 通片的新品上市，并将在患者教育、慢病管理等领域展开合作，联合建设并运营"过敏性鼻炎数字化疾 病中心"，打造覆盖疾病认知、诊疗建议、规范用药到长期随访的全周期健康管理闭环。 《中国变应性鼻炎诊断和治疗指南（2022年）》显示，我国过敏性鼻炎自报患病率达17.6%。2025年12 月，以岭药业研发上市的用于治疗持续性变应性鼻炎（即过敏性鼻炎）一类新药芪防鼻通片在阿里健康 平台全网首发，并于日前纳入2025年国家医保目录。其发表于国际SCI期刊《民族药理学》的Ⅲ期临床 试验显示：治疗4周后，鼻部症状总分改善较对照组提升21.8%，眼部症状改善提升31%。南京医科大学 第一附属医院程雷教授指出，芪防鼻通片的组方同时关注肺虚和脾虚的调理，具有标本兼治的特点。 以岭药业常务副总经理兼营销公司总经理张科源介绍，公司近六年来累计研发投入已超过50亿元，2025 年上半年研发费用占营业收入比重接近10%。并已开展40余项符合国际规范的循证医学研究，多项成果 发表在《美国医学会杂志》《自然》子刊以及《欧洲心脏杂志》等权威期刊。目前 ...

Core Insights - The event on December 8, organized by People's Daily Health Client and supported by Yiling Pharmaceutical, marked the strategic partnership between Yiling Pharmaceutical and Alibaba Health to create a digital disease center for allergic rhinitis, integrating traditional Chinese medicine with modern digital health services [1][4] - The launch of the new product, Qifang Bitong Pian, was announced, which will be exclusively available on Alibaba Health [1][7] Group 1: Strategic Collaboration - Yiling Pharmaceutical and Alibaba Health signed a strategic cooperation agreement to develop a digital disease center for allergic rhinitis, aiming to provide authoritative education and precise services for patients [1][4] - The partnership seeks to bridge traditional Chinese medicine with modern digital health ecosystems, enhancing patient access to treatment [1][4] Group 2: Clinical Insights and Treatment Approaches - Allergic rhinitis incidence is rising, significantly affecting daily life, with environmental factors like vegetation changes and climate fluctuations contributing to its prevalence [2] - Traditional Chinese medicine (TCM) offers distinct advantages in treating allergic rhinitis, focusing on immune function regulation and long-term symptom relief through methods like Qi tonification and spleen strengthening [5][6] Group 3: Product Innovation - Qifang Bitong Pian, a class 1 innovative traditional Chinese medicine developed by Yiling Pharmaceutical, is set to be launched in January 2025 and has been included in the national medical insurance directory [6] - The product combines classic formulas and new ingredients, demonstrating efficacy in alleviating symptoms of allergic rhinitis and improving overall patient safety [6] Group 4: Policy and Market Dynamics - The integration of TCM into the medical insurance system is evolving, with recent policies supporting the inclusion of TCM innovations and emphasizing the need for evidence-based practices [8] - Yiling Pharmaceutical is committed to technological innovation and market transformation, having established over 60 compliant traditional Chinese medicine cultivation bases across the country [9]

Group 1 - The Second China Respiratory Health Conference was held in Guangzhou, gathering over 1,200 experts and scholars in the field of respiratory diseases for academic exchanges [2] - Yiling Pharmaceutical showcased its innovative drug research results in the respiratory field and was granted membership in the "Traditional Chinese Medicine Respiratory Health Development Community" [2][9] - The conference marked the official launch of the "Traditional Chinese Medicine Respiratory Health Development Community" for 2026 [4] Group 2 - Academicians Zhang Boli and Zhong Nanshan visited Yiling Pharmaceutical's booth, where the company presented key respiratory products such as Lianhua Qingwen Capsules and Lianhua Qingke Tablets [3][6] - Lianhua Qingwen Capsules, an innovative drug for treating colds and influenza, has been included in the traditional Chinese medicine prevention and treatment plans in provinces like Shandong and Sichuan [3] - Yiling Pharmaceutical has established a unique development model based on the theory of network diseases, integrating theory, clinical practice, new drug development, industry, and education [6] Group 3 - The company is focusing on evidence-based medicine to validate the efficacy of traditional Chinese medicine, with over 120 SCI papers published on Lianhua Qingwen since its launch [6] - Yiling Pharmaceutical has built a comprehensive industrial capability, achieving standardized control from raw material planting to drug production and market circulation [6] - The company aims to actively participate in the community's initiatives, integrating internal and external resources for collaborative research and academic promotion in the respiratory health field [9][7]